Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Content :

Update on Insuman®

January 10, 2017

End of temporary shortage supply of Insulin human - INSUMAN® BASAL, COMB 25 – suspension for injection in 3 mL cartridges and prefilled pens

 

In November 2015 Sanofi provided notification of the lack of availability of Insuman® Basal and Comb 25.

In agreement with the Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency, Sanofi would like to confirm the resolution of the market shortage of Insuman® (recombinant human insulin) in the United Kingdom.

The cause of the shortage was the limited manufacturing capacity at the Sanofi manufacturing site.

The presentations concerned are:

  • Insuman® Basal 100 IU/mL suspension for injection in a cartridge
  • Insuman® Comb 25 100 IU/mL suspension for injection in a cartridge
  • Insuman® Basal Solostar® 100 IU/mL suspension for injection in a pre-filled pen
  • Insuman® Comb 25 Solostar® 100 IU/mL suspension for injection in a pre-filled pen

Normal production resumed in September 2016. Stocks in the different distribution centers, hospitals and pharmacies are currently being replenished and will be back to normal by the end of March 2017.

Further information - implications for patients

The re-conversion of patients initially treated with Insuman®, who were switched to an alternative insulin and who would like to come back to Insuman®, should be performed under the supervision of a Healthcare Professional and with close monitoring of blood glucose levels. Patients may need to be trained again in the use of the Insuman delivery device that is specific to each device manufacturer.

Call for reporting

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

The following should be reported:

  • all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason.
  • all suspected ADRs associated with new drugs and vaccines identified by the black triangle

Reports can also be made to the Sanofi UK Pharmacovigilance department at:Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK. Tel: 01483 554242, Fax: 01483 554806, Email: uk-drugsafety@sanofi.com

Company contact point

Should you have any question or require additional information, please call Medical Information at Sanofi, One Onslow Street, Guildford, Surrey, GU1 4YS, UK - Tel: 0845 372 7101, Email: uk-medicalinformation@sanofi.com. For questions relating to order of product: Sanofi Customer Services – 0800 854 430, (9am – 5.15pm Monday-Thursday, 9am – 4pm Friday).

January 2017 - SAGB.INA.16.12.1119b

Module :

Corporate Information

Corporate Information

 

Sanofi Diabetes Products

If you have any questions relating to any of Sanofi's diabetes products or services, or experience difficulty in getting supply of any Sanofi diabetes products,

or

Sanofi in the UK

Find out more about Sanofi UK's business units and locations, our investment in research and development, and our product pipeline